Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival

Is the Bellmunt Risk Score (BRS) a valid prognostic tool for predicting survival in patients with metastatic castration-resistant prostate cancer (mCRPC)?In this prognostic study using data for 1756 patients with mCRPC in the ACIS and ELM-PC-5 phase 3 trials, having a higher BRS was consistently associated with unfavorable overall survival and radiographic progression-free survival. The BRS remained a robust and independent prognostic factor for both outcomes in multivariable models.These findings suggest that the BRS provides validated and clinically meaningful prognostic information that can aid in guiding treatment decisions and risk stratification in patients with mCRPC.

Corresponding Author: Thomas Büttner, MD, Department of Urology and Pediatric Urology, University Hospital Bonn, Venusberg-Campus 1, Bonn 53127, Germany (thomas.buettner@ukbonn.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.